Latest News
-
Rs 17/Share Dividend: Record Date On April 26; Buy The ICICI Group Stock To Be Eligible? -
Honasa Consumer to Strengthen Operations by Merging Fusion Cosmeceutics and Just4Kids -
Wipro Reports 7.8% Decline in Q4 Net Profit; CEO Highlights Economic Challenges -
IREDA Hits Record Annual PAT of Rs 1,252 Cr in FY24; Q4 Profits Up by 33% -
Massive Employee Exodus Hits India's Top IT Companies in FY23-24 -
Air India Enhances Operational Efficiency with New Crew Management System -
BlackRock Acquires Shares in Electrosteel Castings and PTC India for Rs 207 Crore -
IndiGo Enhances Domestic Routes with Direct Chennai-Durgapur Flights -
Tesla to Recall Nearly 4,000 Cybertrucks Over Accelerator Pedal Fault -
Reliance, ONGC, Tata, Adanis: Energy Stocks Didn't Get The Memo Of Bears, Up 12% In 30-Days; 10 Stocks To BUY
For Daily Alerts
Aurobindo Pharma gains 10% in three days on USFDA approval
Aurobindo Pharma has been rising ever since the company secured final approval from the USFDA to manufacture & market Amlodipine Besylate and Benazepril Hydrochloride Capsules.
The company is an integrated pharma company, which features among the top 10 companies in India in terms of consolidated revenues.
Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations.
GoodReturns.in
More From GoodReturns
